Case number 2019-1650
Amgen Inc. v. Watson Laboratories, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 9, 2020 | 122 | ORDER granting motion to dismiss appeal pursuant to FRAP 42(b) [121] filed by Appellees Watson Laboratories, Inc., Actavis Pharma, Inc. and Appellant Amgen Inc.; issuing mandate. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [706350] [19-1650, 19-1770] [JAB] [Entered: 07/09/2020 12:18 PM] (2) |
| Jul 8, 2020 | 121 | MOTION of Appellant Amgen Inc. and Appellees Watson Laboratories, Inc. and Actavis Pharma, Inc. to voluntarily dismiss appeal pursuant to FRAP 42(b). [Consent: unopposed]. Service: 07/08/2020 by email. [706233] [19-1650] [Bradford Badke] [Entered: 07/08/2020 08:59 PM] (7) |
| Jul 2, 2020 | 120 | **TEXT ONLY** ORDER granting motion to withdraw attorney Zachary L. Sorman [119] filed by Appellees Watson Laboratories, Inc. and Actavis Pharma, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [705082] [JAB] [Entered: 07/02/2020 07:55 AM] (0) |
| Jul 1, 2020 | 119 | MOTION of Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. to withdraw counsel Zachary L. Sorman [Consent: unopposed]. Service: 07/01/2020 by email. [705025] [19-1650] [Geoffrey Eaton] [Entered: 07/01/2020 04:37 PM] (5) |
| Jun 19, 2020 | 118 | Clerk's letter to Appellant Amgen Inc. and Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. regarding Telephonic Argument Orientation. Service as of this date by the Clerk of Court. [702505] [JAB] [Entered: 06/19/2020 01:57 PM] (0) |
| Jun 4, 2020 | 117 | ORDER filed denying [91] motion to allow argument filed by Cipla Limited and Cipla USA Inc. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [699264] [JAB] [Entered: 06/04/2020 02:35 PM] (2) |
| Jun 3, 2020 | 116 | Response to notice of oral argument from the Appellant Amgen Inc.. [699062] [19-1650] [Bradford Badke] [Entered: 06/03/2020 05:45 PM] (3) |
| May 21, 2020 | 114 | NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2007J. Case scheduled July 9, 2020. Response to Notice of Oral Argument due: 06/15/2020. The Clerk's Office will provide additional instructions to counsel at least one week ahead of argument. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [696324] [JAB] [Entered: 05/21/2020 03:15 PM] (1) |
| May 21, 2020 | 115 | Response to notice of oral argument from the Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. [696430] [19-1650] [George Lombardi] [Entered: 05/21/2020 05:15 PM] (3) |
| Mar 26, 2020 | 112 | Amended Entry of appearance for Geoffrey P. Eaton as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/26/2020 by email. [681985] [19-1650] [Geoffrey Eaton] [Entered: 03/26/2020 12:29 PM] (2) |
| Mar 26, 2020 | 113 | Amended Entry of appearance for Lauren Gailey as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/26/2020 by email. [681987] [19-1650] [Lauren Gailey] [Entered: 03/26/2020 12:32 PM] (2) |
| Mar 12, 2020 | 111 | MODIFIED ENTRY: RESPONSE of Appellant Amgen Inc. to the supplemental authority [109] filed by Amici Curiae Cipla Limited and Cipla USA Inc.. Service: 03/12/2020 by email. [678393]--[Edited 03/13/2020 by JCA - Reason: to correct filing event] [Bradford Badke] [Entered: 03/12/2020 05:11 PM] (3) |
| Feb 27, 2020 | 110 | MODIFIED ENTRY: RESPONSE of Appellant Amgen Inc. to the supplemental authority [107] filed by Appellees Watson Laboratories, Inc. and Actavis Pharma, Inc. in 19-1650. Service: 02/27/2020 by email. [674817]--[Edited 05/22/2020 by JCA - Reason: to correct filing event] [Bradford Badke] [Entered: 02/27/2020 01:23 PM] (3) |
| Feb 26, 2020 | 108 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Amici Curiae Cipla Limited and Cipla USA Inc.. Service: 02/26/2020 by email. [674355] [19-1650] [James Dabney] [Entered: 02/26/2020 01:03 PM] (3) |
| Feb 26, 2020 | 109 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Amici Curiae Cipla Limited and Cipla USA Inc.. Service: 02/26/2020 by email. [674447] [19-1650] [James Dabney] [Entered: 02/26/2020 02:56 PM] (3) |
| Feb 19, 2020 | 107 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 02/19/2020 by email. [672615] [19-1650] [George Lombardi] [Entered: 02/19/2020 05:44 PM] (3) |
| Jan 7, 2020 | 105 | ORDER deferring motion to allow argument [91] to merits panel assigned to hear this case. Service as of this date by the Clerk of Court. [661139] [JAL] [Entered: 01/07/2020 08:42 AM] (2) |
| Jan 7, 2020 | 106 | The following conflict dates submitted by Attorney James W. Dabney for Amici Curiae Cipla Limited and Cipla USA Inc. have been accepted by the court: 03/02/2020, 03/03/2020, 04/06/2020, 04/07/2020. [661281] [JAB] [Entered: 01/07/2020 01:41 PM] (0) |
| Jan 2, 2020 | 104 | REPLY of Amici Curiae Cipla Limited and Cipla USA Inc. to response [100], response [103]. Service: 01/02/2020 by email. [660377] [19-1650] [James Dabney] [Entered: 01/02/2020 05:33 PM] (10) |
| Dec 26, 2019 | 100 | RESPONSE of Appellant Amgen Inc. to the motion to allow argument [91] filed by Amici Curiae Cipla Limited and Cipla USA Inc. Service: 12/26/2019 by email. [658818] [19-1650] [Bradford Badke] [Entered: 12/26/2019 12:08 PM] (12) |
| Dec 26, 2019 | 101 | The following conflict dates submitted by Attorney Bradford J. Badke for Appellant Amgen Inc. have been accepted by the court: 03/02/2020, 03/03/2020, 03/04/2020, 03/05/2020, 03/06/2020, 06/01/2020, 06/02/2020, 06/03/2020, 06/04/2020, 06/05/2020. [658892] [JAB] [Entered: 12/26/2019 02:16 PM] (0) |
| Dec 26, 2019 | 102 | The following conflict dates submitted by Attorney George C. Lombardi for Appellees Watson Laboratories, Inc. and Actavis Pharma, Inc. have been accepted by the court: 03/02/2020, 03/03/2020, 03/04/2020, 03/05/2020, 03/06/2020, 05/04/2020, 05/05/2020, 05/06/2020, 05/07/2020, 05/08/2020. [658893] [JAB] [Entered: 12/26/2019 02:17 PM] (0) |
| Dec 26, 2019 | 103 | RESPONSE of Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. to the motion to allow argument [91] filed by Amici Curiae Cipla Limited and Cipla USA Inc. Service: 12/26/2019 by email. [658973] [19-1650] [Geoffrey Eaton] [Entered: 12/26/2019 05:25 PM] (6) |
| Dec 20, 2019 | 99 | Notice from Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. regarding conflicts with oral argument. Service: 12/20/2019 by email. [658333] [19-1650] [George Lombardi] [Entered: 12/20/2019 05:11 PM] (3) |
| Dec 19, 2019 | 98 | Notice from Appellant Amgen Inc. regarding conflicts with oral argument. Service: 12/19/2019 by email. [657847] [19-1650] [Bradford Badke] [Entered: 12/19/2019 02:18 PM] (3) |
| Dec 18, 2019 | 97 | Notice from Amici Curiae Cipla Limited and Cipla USA Inc. regarding conflicts with oral argument. Service: 12/18/2019 by email. [657639] [19-1650] [James Dabney] [Entered: 12/18/2019 04:35 PM] (2) |
| Dec 17, 2019 | 95 | 6 paper copies of the Opening Response Brief [72] received from Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. [657140] [CJF] [Entered: 12/17/2019 01:43 PM] (0) |
| Dec 17, 2019 | 96 | 6 paper copies of the Amicus Brief [71] received from Amici Curiae Cipla Limited and Cipla USA Inc.. [657141] [CJF] [Entered: 12/17/2019 01:44 PM] (0) |
| Dec 16, 2019 | 91 | MOTION of Amici Curiae Cipla Limited and Cipla USA Inc. to allow argument [Consent: opposed]. Service: 12/16/2019 by email. [656930] [19-1650] [James Dabney] [Entered: 12/16/2019 05:17 PM] (6) |
| Dec 16, 2019 | 92 | 6 paper copies of the Confidential Opening Brief [39] received from Appellant Amgen Inc.. [657098] [CJF] [Entered: 12/17/2019 11:22 AM] (0) |
| Dec 16, 2019 | 93 | 6 paper copies of the Confidential Reply Brief [77] received from Appellant Amgen Inc.. [657099] [CJF] [Entered: 12/17/2019 11:23 AM] (0) |
| Dec 16, 2019 | 94 | 6 paper copies of the Corrected Confidential Joint Appendix (Vol. I - II) [86] received from Appellant Amgen Inc.. [657102] [CJF] [Entered: 12/17/2019 11:25 AM] (0) |
| Dec 13, 2019 | 88 | ORDER filed granting motion to waive the requirements of Federal Circuit Rule 28(d)(1)(A) [79] filed by Appellant. The confidential and nonconfidential versions of Amgen’s reply brief are accepted for filing.; denying as moot motion to extend time to file appendix [76] filed by Appellant Amgen Inc. Service as of this date by the Clerk of Court. [656466] [NL] [Entered: 12/13/2019 12:48 PM] (3) |
| Dec 13, 2019 | 89 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(1). [656482] [JAL] [Entered: 12/13/2019 01:15 PM] (0) |
| Dec 13, 2019 | 90 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [656483] [JAL] [Entered: 12/13/2019 01:15 PM] (1) |
| Dec 4, 2019 | 85 | Notice of Correction to Doc No. [80], [81] for Appellant Amgen Inc.. Service: 12/04/2019 by email. [654180] [19-1650] [Bradford Badke] [Entered: 12/04/2019 07:35 PM] (5) |
| Dec 4, 2019 | 86 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL JOINT APPENDIX FILED for Appellant Amgen Inc.. Number of Pages: 782. Service: 12/04/2019 by email. [654183]--[Edited 12/06/2019 by JAL - Compliance review complete] [Bradford Badke] [Entered: 12/04/2019 07:37 PM] (0) |
| Dec 4, 2019 | 87 | MODIFIED ENTRY: CORRECTED JOINT APPENDIX FILED for Appellant Amgen Inc. Number of Pages: 460. Service: 12/04/2019 by email. [654184] --[Edited 12/06/2019 by JAL - Compliance review complete] [Bradford Badke] [Entered: 12/04/2019 07:39 PM] (460) |
| Dec 2, 2019 | 80 | FILED from Appellant Amgen Inc.. Title: CONFIDENTIAL APPENDIX. Service: 12/02/2019 by email. [653393] [19-1650] This brief has been corrected. See Doc No.[86]--[Edited 12/05/2019 by JAL to reflect document correction] [Bradford Badke] [Entered: 12/02/2019 11:44 PM] (0) |
| Dec 2, 2019 | 81 | FILED from Appellant Amgen Inc.. Title: APPENDIX. Service: 12/02/2019 by email. [653394] [19-1650] This brief has been corrected. See Doc No. [87]--[Edited 12/05/2019 by JAL to reflect document correction] [Bradford Badke] [Entered: 12/02/2019 11:46 PM] (428) |
| Dec 2, 2019 | 82 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellees Actavis Pharma, Inc., Watson Laboratories, Inc. and Appellant Amgen Inc.. Service: 12/02/2019 by email. [653395] [19-1650] [Bradford Badke] [Entered: 12/02/2019 11:51 PM] (4) |
| Dec 2, 2019 | 83 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Amgen Inc.. Service: 12/02/2019 by email. [653396] [19-1650] [Bradford Badke] [Entered: 12/02/2019 11:53 PM] (3) |
| Dec 2, 2019 | 84 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 12/02/2019 by email. [653398] [19-1650] [George Lombardi] [Entered: 12/02/2019 11:59 PM] (3) |
| Nov 25, 2019 | 77 | MODIFIED ENTRY: CONFIDENTIAL REPLY BRIEF FILED for Appellant Amgen Inc. Number of Pages: 31. Service: 11/25/2019 by email. [652304]--[Edited 12/13/2019 by JAL - Accepted pursuant to court order [88]] [Bradford Badke] [Entered: 11/25/2019 10:42 PM] (0) |
| Nov 25, 2019 | 78 | MODIFIED ENTRY: REPLY BRIEF FILED for Appellant Amgen Inc. Number of Pages: 31. Service: 11/25/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [652305] --[Edited 12/13/2019 by JAL - Accepted pursuant to court order [88]] [Bradford Badke] [Entered: 11/25/2019 10:44 PM] (42) |
| Nov 25, 2019 | 79 | MODIFIED ENTRY: MOTION of Amgen Inc. to waive confidentiality requirements [Consent: unopposed]. Service: 11/25/2019 by email. [652306]--[Edited 11/26/2019 by MJL to correct relief] [Bradford Badke] [Entered: 11/25/2019 10:48 PM] (39) |
| Nov 20, 2019 | 76 | MOTION of Appellant Amgen Inc. to extend the time to 12/09/2019 to file the appendix. [Consent: unopposed]. Service: 11/20/2019 by email. [650797] [19-1650] [Bradford Badke] [Entered: 11/20/2019 10:56 AM] (9) |
| Nov 6, 2019 | 73 | Notice to counsel for Amici Curiae Cipla Limited and Cipla USA Inc.: The record of this case indicates that the Certificate of Interest has not been filed. Service as of this date by the Clerk of Court. [647417] [JAL] [Entered: 11/06/2019 02:27 PM] (0) |
| Nov 6, 2019 | 74 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a) to promptly submit an amended Certificate of Interest as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [647428] [JAL] [Entered: 11/06/2019 02:33 PM] (0) |
| Nov 6, 2019 | 75 | Certificate of Interest for Amici Curiae Cipla Limited and Cipla USA Inc.. Service: 11/06/2019 by email. [647438] [19-1650] [James Dabney] [Entered: 11/06/2019 02:45 PM] (3) |
| Nov 4, 2019 | 69 | Entry of appearance for David E. Lansky as of counsel for Amici Curiae Cipla Limited and Cipla USA Inc.. Service: 11/04/2019 by email. [646647] [19-1650] [David Lansky] [Entered: 11/04/2019 11:23 AM] (2) |
| Nov 4, 2019 | 70 | Entry of appearance for Lynn Russo as of counsel for Amici Curiae Cipla Limited and Cipla USA Inc.. Service: 11/04/2019 by email. [646776] [19-1650] [Lynn Russo] [Entered: 11/04/2019 04:01 PM] (2) |
| Nov 4, 2019 | 71 | MODIFIED ENTRY: AMICUS BRIEF FILED for Amici Curiae Cipla Limited and Cipla USA Inc. Pages: 29. Service: 11/04/2019 by email. [646799]--[Edited 11/06/2019 by JAL - Compliance review complete] [James Dabney] [Entered: 11/04/2019 04:31 PM] (38) |
| Nov 4, 2019 | 72 | MODIFIED ENTRY: RESPONSE BRIEF FILED for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. Number of Pages: 59. Service: 11/04/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [646825] --[Edited 11/06/2019 by JAL - Compliance review complete] [George Lombardi] [Entered: 11/04/2019 05:51 PM] (74) |
| Oct 31, 2019 | 68 | Official caption revised to reflect designation of Cipla Limited and Cipla USA Inc. as amici curiae (see 09/13/2019 order [57]. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [646164] [JAL] [Entered: 10/31/2019 02:31 PM] (0) |
| Oct 29, 2019 | 66 | Entry of appearance for Richard M Koehl as of counsel for Cipla Ltd. and Cipla USA Inc. (pursuant to ECF 57). Service: 10/29/2019 by email. [645439] [19-1650] [Richard Koehl] [Entered: 10/29/2019 11:03 AM] (2) |
| Oct 29, 2019 | 67 | Entry of appearance for Deanne K. Cevasco as of counsel for Cipla Ltd. and Cipla USA Inc.. Service: 10/29/2019 by email. [645538] [19-1650] [Deanne Cevasco] [Entered: 10/29/2019 01:48 PM] (2) |
| Oct 18, 2019 | 65 | ORDER granting-in-part motion [58]. The motion is granted to the extent that Amgen shall serve on Cipla’s outside appellate counsel: (1) a copy of Amgen’s opening brief in which the statement of the case (pages 6–15) and section I of the argument (pages 19–37) are unredacted; and (2) portions of the addendum and appendix materials cited in those portions of the opening brief. Service as of this date by the Clerk of Court. [643031] [NL] [Entered: 10/18/2019 10:04 AM] (3) |
| Sep 25, 2019 | 64 | REPLY of Cipla Ltd. and Cipla USA, Inc. to response [63]. Service: 09/25/2019 by email. [638293] [19-1650] [James Dabney] [Entered: 09/25/2019 05:02 PM] (11) |
| Sep 23, 2019 | 63 | RESPONSE of Appellant Amgen Inc. to the motion for other relief [58] , motion to expedite other [58]. Service: 09/23/2019 by email. [637629] [19-1650] [Bradford Badke] [Entered: 09/23/2019 08:45 PM] (26) |
| Sep 20, 2019 | 61 | RESPONSE of Appellee Watson Laboratories, Inc. to the motion for other relief [58] , motion to expedite other [58]. Service: 09/20/2019 by email. [637015] [19-1650] [Geoffrey Eaton] [Entered: 09/20/2019 11:54 AM] (4) |
| Sep 20, 2019 | 62 | ORDER granting motion to extend time to file brief [60]. Watson’s response brief and Cipla Ltd. and Cipla USA, Inc.’s amicus curiae brief are due no later than November 4, 2019. Service as of this date by the Clerk of Court. [637073] [NL] [Entered: 09/20/2019 02:30 PM] (2) |
| Sep 18, 2019 | 59 | ORDER Any response to the motion [58] is due no later than September 23, 2019. Any reply is due no later than September 25, 2019. Service as of this date by the Clerk of Court. [636402] [LMS] [Entered: 09/18/2019 01:27 PM] (2) |
| Sep 18, 2019 | 60 | MOTION of Appellees Watson Laboratories, Inc. and Actavis Pharma, Inc. to extend the time to 11/04/2019 to file the Appellees' Brief. [Consent: unopposed]. Service: 09/18/2019 by email. [636576] [19-1650] [Geoffrey Eaton] [Entered: 09/18/2019 08:01 PM] (8) |
| Sep 17, 2019 | 58 | MOTION of Cipla Ltd. and Cipla USA, Inc. Expedited Motion to Compel Service of Appellant's Brief and Appendix Designations, to expedite. [Consent: opposed]. Service: 09/17/2019 by email. [636244] [19-1650] [James Dabney] [Entered: 09/17/2019 09:27 PM] (75) |
| Sep 13, 2019 | 57 | ORDER filed lifting the stay of the briefing schedule. Amgen's motion [46] is denied. Cipla's motion [49] is granted to the extent that it may file a brief amicus curiae. Any request by Cipla to participate at oral argument must be made by separate motion, which shall be deferred to the merits panel assigned to these appeals. Watson's response brief and Cipla's amicus curiae brief are due no later than October 4, 2019. A copy of this order shall be transmitted to the assigned merits panel.; - FOR CALENDAR. Service as of this date by the Clerk of Court. [635427] [LMS] [Entered: 09/13/2019 02:14 PM] (3) |
| Aug 5, 2019 | 56 | REPLY of Cipla Ltd. and Cipla USA, Inc. to response [53], response [55]. Service: 08/05/2019 by email. [626124] [19-1650] [James Dabney] [Entered: 08/05/2019 07:43 PM] (34) |
| Jul 31, 2019 | 54 | Notice of Correction to the response Doc No. [53] for Appellant Amgen Inc.. Service: 07/31/2019 by email. [625043] [19-1650] [Bradford Badke] [Entered: 07/31/2019 07:30 PM] (4) |
| Jul 31, 2019 | 55 | RESPONSE of Appellant Amgen Inc. to the motion for leave to intervene [49]. Service: 07/31/2019 by email. [625044] [19-1650] [Bradford Badke] [Entered: 07/31/2019 07:35 PM] (26) |
| Jul 29, 2019 | 53 | RESPONSE of Appellant Amgen Inc. to the motion for leave to intervene [49]. Service: 07/29/2019 by email. [624329] [19-1650] This document has been corrected. See Doc No.[55]--[Edited 08/01/2019 by JAL to revise docket text] [Bradford Badke] [Entered: 07/29/2019 08:03 PM] (26) |
| Jul 23, 2019 | 52 | ORDER filed. The motion for an extension of time [51] is granted to the extent that Amgen's response is due no later than July 29, 2019. Service: 07/23/2019 by clerk. [622856] [LMS] [Entered: 07/23/2019 11:53 AM] (2) |
| Jul 22, 2019 | 51 | MOTION of Appellant Amgen Inc. to extend the time to 07/29/2019 to file Response/Reply [Consent: unopposed]. Service: 07/22/2019 by email. [622647] [19-1650] [Bradford Badke] [Entered: 07/22/2019 05:06 PM] (10) |
| Jul 19, 2019 | 50 | ORDER filed. The motion for an extension of time [47] is granted to the extent that the briefing schedule is stayed pending disposition of the motion to vacate. Service: 07/19/2019 by clerk. [622258] [LMS] [Entered: 07/19/2019 02:26 PM] (2) |
| Jul 18, 2019 | 48 | Entry of appearance for James W. Dabney as principal counsel for Cipla Limited and Cipla USA Inc.. Service: 07/18/2019 by email. [622064] [19-1650] [James Dabney] [Entered: 07/18/2019 04:40 PM] (2) |
| Jul 18, 2019 | 49 | RESPONSE to the motion [46] filed by Appellant Amgen Inc.with MOTION to for leave to intervene, Opposition to Motion, Conditional Motion to Intervene, and Suggestion of Mootness Service: 07/18/2019 by email [622083] [19-1650] [James Dabney] [Entered: 07/18/2019 06:14 PM] (34) |
| Jul 17, 2019 | 44 | ORDER filed. The motion [40] is granted. The confidential and nonconfidential versions of Amgen's opening brief are accepted for filing. Service: 07/17/2019 by clerk. [621745] [LMS] [Entered: 07/17/2019 02:36 PM] (2) |
| Jul 17, 2019 | 45 | ORDER filed. The motion [42] is granted. Service: 07/17/2019 by clerk. [621755] [LMS] [Entered: 07/17/2019 02:46 PM] (2) |
| Jul 17, 2019 | 46 | MOTION of Appellant Amgen Inc. to vacate the The district court's July 27, 2018 Opinion and Trial Order (Dkt. Nos. 375, 376) and August 24, 2018 Final Judgment and Order (Dkt. Nos. 384, 386) as they relate to Watson.. [Consent: unopposed]. Service: 07/17/2019 by email. [621776] [19-1650] [Bradford Badke] [Entered: 07/17/2019 03:51 PM] (10) |
| Jul 17, 2019 | 47 | MOTION of Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. to extend the time to 10/04/2019 to file the Appellees' Brief. [Consent: unopposed]. Service: 07/17/2019 by email. [621820] [19-1650] [Geoffrey Eaton] [Entered: 07/17/2019 05:11 PM] (8) |
| Jul 11, 2019 | 42 | MOTION of Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc. to withdraw counsel Steffen N. Johnson [Consent: unopposed]. Service: 07/11/2019 by email. [620365] [19-1650] [Christopher Essig] [Entered: 07/11/2019 02:56 PM] (5) |
| Jul 11, 2019 | 43 | Entry of appearance for Geoffrey P. Eaton as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 07/11/2019 by email. [620368] [19-1650] [Geoffrey Eaton] [Entered: 07/11/2019 03:10 PM] (2) |
| Jul 10, 2019 | 41 | Entry of appearance for Lauren Gailey as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 07/10/2019 by email. [620097] [19-1650] [Lauren Gailey] [Entered: 07/10/2019 03:06 PM] (2) |
| Jun 24, 2019 | 38 | MODIFIED ENTRY: OPENING BRIEF FILED for Appellant Amgen Inc. Number of Pages: 54. Service: 06/24/2019 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [616590] --[Edited 07/17/2019 by JAL - Compliance review complete] [Bradford Badke] [Entered: 06/24/2019 11:38 PM] (165) |
| Jun 24, 2019 | 39 | MODIFIED ENTRY: CONFIDENTIAL OPENING BRIEF FILED for Appellant Amgen Inc. Number of Pages: 54. Service: 06/24/2019 by email. [616592]--[Edited 07/17/2019 by JAL - Compliance review complete] [Bradford Badke] [Entered: 06/24/2019 11:41 PM] (0) |
| Jun 24, 2019 | 40 | MOTION of Appellant Amgen Inc. to waive confidentiality requirements for brief [39] [Consent: unopposed]. Service: 06/24/2019 by email. [616593] [19-1650]--[Edited 06/25/2019 by JAL to correct relief] [Bradford Badke] [Entered: 06/24/2019 11:57 PM] (40) |
| Jun 11, 2019 | 37 | Official caption revised to reflect non-participation of Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Piramal Healthcare UK Limited, Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA) Inc. The revised official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by the Clerk of Court. [613103] [JAL] [Entered: 06/11/2019 01:11 PM] (0) |
| May 24, 2019 | 36 | Notice to counsel for Appellees Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Piramal Healthcare UK Limited, Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA) Inc.: The record of this case indicates that the Entry of Appearance, Certificate of Interest, and Docketing Statement have not been filed. Completed preliminary documents are due by 06/03/2019. Service as of this date by the Clerk of Court. [609567] [JAL] [Entered: 05/24/2019 11:46 AM] (0) |
| Apr 30, 2019 | 29 | Amended Entry of appearance for Alicia A. Russo as of counsel for Appellant Amgen Inc.. Service: 04/30/2019 by email. [603947] [19-1650] [Bradford Badke] [Entered: 04/30/2019 11:04 AM] (2) |
| Apr 30, 2019 | 30 | Amended Entry of appearance for John D. Murnane as of counsel for Appellant Amgen Inc.. Service: 04/30/2019 by email. [603948] [19-1650] [Bradford Badke] [Entered: 04/30/2019 11:05 AM] (2) |
| Apr 30, 2019 | 31 | Amended Entry of appearance for Joshua I. Rothman as of counsel for Appellant Amgen Inc.. Service: 04/30/2019 by email. [603952] [19-1650] [Bradford Badke] [Entered: 04/30/2019 11:06 AM] (2) |
| Apr 30, 2019 | 32 | Corrected Docketing Statement for the Appellant Amgen Inc.. Service: 04/30/2019 by email. [603955] [19-1650] This document is non-compliant. See Doc No.[34] [Bradford Badke] [Entered: 04/30/2019 11:08 AM] (3) |
| Apr 30, 2019 | 33 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [29], attorney entry of appearance Docket No. [30], attorney entry of appearance Docket No. [31], ERROR: The amended entries of appearance for A. Russo [29], J. Murnane [30], and J. Rothman [31] do not list all member cases of a consolidated group of appeals. CORRECTION: For future filings, please include all consolidated case numbers (19-1770) in addition to the lead case number (19-1650). THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [603988] [JAL] [Entered: 04/30/2019 11:38 AM] (0) |
| Apr 30, 2019 | 34 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Amgen Inc., Corrected Docketing Statement [32], is not in compliance with the rules of this court (see attached). Compliant document is due on 05/07/2019. Service as of this date by the Clerk of Court.[603991] [JAL] [Entered: 04/30/2019 11:40 AM] (2) |
| Apr 30, 2019 | 35 | Corrected Docketing Statement for the Appellant Amgen Inc.. Service: 04/30/2019 by email. [604211] [19-1650] [Bradford Badke] [Entered: 04/30/2019 07:43 PM] (3) |
| Apr 29, 2019 | 26 | ORDER filed. The stay of Appeal No. 19-1650 is lifted, and it and Appeal No. 2019-1770 are consolidated. One set of briefs should be filed for the two appeals. Amgen’s opening brief is due no later than 60 days from the date of filing of this order. Service: 04/29/2019 by clerk. [603597] [19-1650, 19-1770] [NL] [Entered: 04/29/2019 12:39 PM] (2) |
| Apr 29, 2019 | 27 | Note to file: The following cases are associated: 19-1650 Lead with 19-1770 Member Case. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [603618] [19-1650, 19-1770] [JAL] [Entered: 04/29/2019 01:49 PM] (0) |
| Apr 29, 2019 | 28 | Clerk's Note to the File: The entry of appearance, certificate of interest, and docketing statement for Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York LLC, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Piramal Healthcare UK Limited, Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., Sun Pharamceutical Industries, Ltd., and Zydus Pharmaceuticals (USA) Inc. are due 05/13/2019. [603631] [JAL] [Entered: 04/29/2019 01:59 PM] (0) |
| Apr 10, 2019 | 25 | Notice from Appellant Amgen Inc. regarding postjudgment motions. Service: 04/10/2019 by email. [599136] [19-1650] [Bradford Badke] [Entered: 04/10/2019 07:45 PM] (14) |
| Mar 29, 2019 | 24 | This entry was made in error and has been removed from the docket. Notice to counsel for Appellant Amgen Inc.: The record of this case indicates that the fee has not been paid for this case [1]. Please pay the fee promptly. Service as of this date by the Clerk of Court. [596437] [JAL] [Entered: 03/29/2019 10:19 AM] (0) |
| Mar 28, 2019 | 20 | Docketing Statement for the Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/28/2019 by email. [596362] [19-1650] [Christopher Essig] [Entered: 03/28/2019 07:06 PM] (5) |
| Mar 28, 2019 | 21 | Certificate of Interest for the Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/28/2019 by email. [596363] [19-1650] [Christopher Essig] [Entered: 03/28/2019 07:11 PM] (5) |
| Mar 28, 2019 | 22 | Docketing Statement for the Appellant Amgen Inc.. Service: 03/28/2019 by email. [596364] [19-1650] [Bradford Badke] [Entered: 03/28/2019 07:43 PM] (3) |
| Mar 28, 2019 | 23 | Certificate of Interest for the Appellant Amgen Inc.. Service: 03/28/2019 by email. [596365] [19-1650] [Bradford Badke] [Entered: 03/28/2019 07:45 PM] (3) |
| Mar 19, 2019 | 16 | Entry of appearance for Christopher B. Essig as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/19/2019 by email. [593982] [19-1650] [Christopher Essig] [Entered: 03/19/2019 03:41 PM] (2) |
| Mar 19, 2019 | 17 | Entry of appearance for Zachary L. Sorman as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/19/2019 by email. [593985] [19-1650] [Zachary Sorman] [Entered: 03/19/2019 03:44 PM] (2) |
| Mar 19, 2019 | 18 | Entry of appearance for George C. Lombardi as principal counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/19/2019 by email. [593988] [19-1650] [George Lombardi] [Entered: 03/19/2019 03:50 PM] (2) |
| Mar 19, 2019 | 19 | Entry of appearance for Steffen N. Johnson as of counsel for Appellees Actavis Pharma, Inc. and Watson Laboratories, Inc.. Service: 03/19/2019 by email. [593990] [19-1650] [Steffen Johnson] [Entered: 03/19/2019 03:53 PM] (2) |
| Mar 18, 2019 | 15 | Entry of appearance for Lauren Cranford Katzeff as of counsel for Appellant Amgen Inc.. Service: 03/18/2019 by email. [593485] [19-1650] [Bradford Badke] [Entered: 03/18/2019 10:31 AM] (2) |
| Mar 15, 2019 | 14 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:attorney entry of appearance Docket No. [11], ERROR: The contact information on the entry of appearance for J. Rothman [11] does not match the information in the attorney's user account. CORRECTION: Please update as needed to ensure that the information on the entry of appearance and in the user account matches. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [593031] [JAL] [Entered: 03/15/2019 09:01 AM] (0) |
| Mar 14, 2019 | 1 | Appeal docketed. Received: 02/01/2019. [592859] Entry of Appearance due 03/28/2019. Certificate of Interest is due on 03/28/2019. Docketing Statement due 03/28/2019. --[Edited 03/29/2019 by CAB to revise docket text and remove fee deadline] [JAL] [Entered: 03/14/2019 01:24 PM] (55) |
| Mar 14, 2019 | 2 | ORDER filed. Appeal No. 19-1650 is stayed pursuant to 02/01/2019 order in 18-2414 [582816-2]. Service as of this date by the Clerk of Court. [592863] [JAL] [Entered: 03/14/2019 01:28 PM] (3) |
| Mar 14, 2019 | 3 | Entry of appearance for Bradford J. Badke as principal counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592955] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:08 PM] (2) |
| Mar 14, 2019 | 4 | Entry of appearance for Sona De as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592956] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:10 PM] (2) |
| Mar 14, 2019 | 5 | Entry of appearance for Joshua J. Fougere as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592957] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:12 PM] (2) |
| Mar 14, 2019 | 6 | Entry of appearance for Ryan C. Morris as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592958] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:16 PM] (2) |
| Mar 14, 2019 | 7 | Entry of appearance for Eric M. Agovino as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592959] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:21 PM] (2) |
| Mar 14, 2019 | 8 | Entry of appearance for Lois M. Kwasigroch as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592961] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:23 PM] (2) |
| Mar 14, 2019 | 9 | Entry of appearance for Wendy A. Whiteford as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592963] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:27 PM] (2) |
| Mar 14, 2019 | 10 | Entry of appearance for John D. Murnane as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592966] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:35 PM] (2) |
| Mar 14, 2019 | 11 | Entry of appearance for Joshua I. Rothman as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592968] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:36 PM] (2) |
| Mar 14, 2019 | 12 | Entry of appearance for Alicia A. Russo as of counsel for Appellant Amgen Inc.. Service: 03/14/2019 by email. [592969] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:38 PM] (2) |
| Mar 14, 2019 | 13 | Notice from Appellant Amgen Inc. regarding postjudgment motions. Service: 03/14/2019 by email. [592971] [19-1650] [Bradford Badke] [Entered: 03/14/2019 05:53 PM] (4) |
